Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 01 2022
01 01 2022
Historique:
received:
05
05
2021
revised:
13
08
2021
accepted:
07
10
2021
pubmed:
15
10
2021
medline:
8
4
2022
entrez:
14
10
2021
Statut:
ppublish
Résumé
To determine (i) the relationship between candidate biomarkers of the antiproliferative (Ki67) response to letrozole and palbociclib alone and combined in ER 307 postmenopausal women with ER Higher baselines ER and PgR were significantly associated with a greater chance of complete cell-cycle arrest (CCCA: Ki67 <2.7%) at 14 weeks and higher baseline Ki67, c-PARP, and CCNE1 with a lower chance. The interaction with treatment was significant only for c-PARP. CCND1 levels were decreased c.20% by letrozole at 2 and 14 weeks but showed a tendency to increase with palbociclib. CCNE1 levels fell 82% (median) in tumors showing CCCA but were unchanged in those with no CCCA. Only 2/9 tumors showed CCCA 3-9 days after stopping palbociclib. High CCNE1 levels were confirmed as a biomarker of resistance to letrozole+palbociclib. Ki67 recovery within 3-9 days of discontinuing palbociclib indicates incomplete suppression of proliferation during the "off" week of its schedule.
Identifiants
pubmed: 34645649
pii: 1078-0432.CCR-21-1628
doi: 10.1158/1078-0432.CCR-21-1628
pmc: PMC9632606
doi:
Substances chimiques
Biomarkers, Tumor
0
Piperazines
0
Pyridines
0
Receptors, Estrogen
0
Letrozole
7LKK855W8I
Receptor, ErbB-2
EC 2.7.10.1
palbociclib
G9ZF61LE7G
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
163-174Subventions
Organisme : Cancer Research UK
Pays : United Kingdom
Informations de copyright
©2021 The Authors; Published by the American Association for Cancer Research.
Références
Lancet Oncol. 2021 Feb;22(2):212-222
pubmed: 33460574
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
J Clin Oncol. 2020 Dec 1;38(34):3977-3979
pubmed: 32954928
Clin Cancer Res. 2021 Sep 1;27(17):4870-4882
pubmed: 33536276
Sci Transl Med. 2015 Nov 11;7(313):313ra182
pubmed: 26560360
Clin Cancer Res. 2017 Aug 1;23(15):4055-4065
pubmed: 28270497
Ann Oncol. 2018 Aug 1;29(8):1755-1762
pubmed: 29893769
Clin Cancer Res. 2014 Apr 1;20(7):1757-1767
pubmed: 24398047
Oncogene. 2020 Jun;39(25):4781-4797
pubmed: 32307447
Breast Cancer Res. 2012 Apr 04;14(2):R57
pubmed: 22475046
Cancer Res. 2003 Oct 1;63(19):6523-31
pubmed: 14559846
N Engl J Med. 2015 Jul 16;373(3):209-19
pubmed: 26030518
Ann Oncol. 2018 Jul 1;29(7):1541-1547
pubmed: 29718092
J Clin Oncol. 2020 Dec 1;38(34):3987-3998
pubmed: 32954927
Curr Opin Genet Dev. 1994 Feb;4(1):120-9
pubmed: 8193531
J Clin Oncol. 2019 Jan 20;37(3):178-189
pubmed: 30523750
Clin Cancer Res. 2019 Dec 15;25(24):7485-7496
pubmed: 31548345
Cancer Cell. 2018 Dec 10;34(6):893-905.e8
pubmed: 30537512
Clin Cancer Res. 2006 Feb 1;12(3 Pt 2):1024s-1030s
pubmed: 16467120
Lancet Oncol. 2020 Nov;21(11):1443-1454
pubmed: 33152284
N Engl J Med. 2018 Nov 15;379(20):1926-1936
pubmed: 30345905
Breast Cancer Res Treat. 2008 Jun;109(3):463-70
pubmed: 17638066
Lancet Oncol. 2015 Jan;16(1):25-35
pubmed: 25524798
Cancer Discov. 2018 Nov;8(11):1390-1403
pubmed: 30206110
J Clin Oncol. 2019 May 10;37(14):1169-1178
pubmed: 30807234
J Clin Oncol. 2005 Apr 10;23(11):2477-92
pubmed: 15767642
J Natl Cancer Inst. 2007 Jan 17;99(2):167-70
pubmed: 17228000
J Clin Oncol. 2002 Feb 15;20(4):1026-35
pubmed: 11844826
Clin Cancer Res. 2020 Feb 1;26(3):566-580
pubmed: 31615937
J Clin Oncol. 2021 May 1;39(13):1458-1467
pubmed: 33769862
Cancer Res. 2016 Apr 15;76(8):2301-13
pubmed: 27020857
N Engl J Med. 2016 Nov 17;375(20):1925-1936
pubmed: 27959613